VTGN
Vistagen Therapeutics, Inc.
Price Chart
Latest Quote
$0.57
+0.04 (+7.10%)
Current Price
| Previous Close | $0.54 |
| Open | $0.53 |
| Day High | $0.57 |
| Day Low | $0.52 |
| Volume | 938,630 |
Stock Information
| Shares Outstanding | 39.62M |
| Total Debt | $1.43M |
| Cash Equivalents | $61.77M |
| Revenue | $789K |
| Net Income | $-67.05M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $22.83M |
| EPS (TTM) | $-1.90 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-37.51M |
| Sales | $789K |
| Income | $-67.05M |
| Book/sh | $1.28 |
| Cash/sh | $1.56 |
| Employees | 59 |
Financial Ratios
| Quick Ratio | 4.57 |
| Current Ratio | 4.67 |
| Debt/Eq | 2.80 |
Returns & Margins
| ROA | -55.53% |
| ROE | -101.55% |
| Gross Margin | 100.00% |
| Operating Margin | -6450.83% |
Ownership
| Insider Ownership | 0.27% |
| Institutional Ownership | 42.26% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.59 |
| P/S | 28.93 |
| P/B | 0.45 |
Analyst Data
| Recommendation | hold |
| Target Price | $0.97 |
Technical Indicators
| SMA20 | $0.60 |
| SMA50 | $0.60 |
| SMA200 | $1.90 |
| RSI | 36.00 |
| ATR | 0.0443 |
| Shares Float | 34.38M |
| Short Float | 7.27% |
| Short Ratio | 2.47 |
| Volatility | 0.29 |
| Rel Volume | 1.12 |
Performance History
| Week | +7.41% |
| Month | -12.12% |
| Quarter | -4.92% |
| 6 Months | -87.20% |
| YTD | -14.71% |
| Year | -75.42% |
| 3 Years | -78.60% |
| 5 Years | -99.25% |
| 10 Years | -99.49% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-12 | $0.58 | 677,800 |
| 2026-06-11 | $0.57 | 958,900 |
| 2026-06-10 | $0.54 | 489,800 |
| 2026-06-09 | $0.54 | 477,800 |
| 2026-06-08 | $0.54 | 520,300 |
| 2026-06-05 | $0.54 | 494,700 |
| 2026-06-04 | $0.58 | 292,600 |
| 2026-06-03 | $0.56 | 572,300 |
| 2026-06-02 | $0.58 | 1,738,900 |
| 2026-06-01 | $0.65 | 614,500 |
| 2026-05-29 | $0.63 | 651,600 |
| 2026-05-28 | $0.63 | 753,700 |
| 2026-05-27 | $0.62 | 327,300 |
| 2026-05-26 | $0.64 | 287,700 |
| 2026-05-22 | $0.65 | 543,100 |
| 2026-05-21 | $0.64 | 261,300 |
| 2026-05-20 | $0.64 | 390,600 |
| 2026-05-19 | $0.63 | 859,100 |
| 2026-05-18 | $0.60 | 543,100 |
| 2026-05-15 | $0.62 | 661,900 |
| 2026-05-14 | $0.65 | 560,200 |
| 2026-05-13 | $0.66 | 885,000 |
About Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
đ° Latest News
HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates
Zacks âĸ 2026-05-28T21:40:03Z
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-20T12:15:02Z
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?
Insider Monkey âĸ 2026-05-19T11:08:57Z
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-18T13:00:01Z
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby âĸ 2026-02-13T13:30:00Z
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...
GuruFocus.com âĸ 2026-02-13T05:02:35ZVistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2026-02-12T22:45:02Z
US Equity Markets Fall as Technology Stocks Slump Amid Oracle Concerns
MT Newswires âĸ 2025-12-17T21:22:44ZVistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ...
GuruFocus.com âĸ 2025-11-14T05:06:24Z
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-13T22:55:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $486,000 | $1,064,000 | $-227,000 | $1,108,900 |
| Operating Revenue | $486,000 | $1,064,000 | $-227,000 | $1,108,900 |
| Expenses | ||||
| Total Expenses | $56,459,000 | $34,085,000 | $59,041,000 | $48,655,800 |
| Other Income Expense | $5,000 | $312,000 | - | $-232,000 |
| Other Non Operating Income Expenses | $5,000 | $312,000 | - | - |
| Net Non Operating Interest Income Expense | $4,557,000 | $3,351,000 | $26,000 | $20,000 |
| Operating Expense | $56,459,000 | $34,085,000 | $59,041,000 | $48,655,800 |
| General And Administrative Expense | $17,084,000 | $14,063,000 | $14,664,000 | $10,452,000 |
| Total Other Finance Cost | - | $-3,351,000 | $-26,000 | - |
| Interest Expense | - | - | $23,000 | $0 |
| Rent Expense Supplemental | - | - | $419,000 | $377,000 |
| Interest Expense Non Operating | - | - | $23,000 | $0 |
| Selling And Marketing Expense | - | - | $1,904,000 | $2,796,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Net Interest Income | $4,557,000 | $3,351,000 | $26,000 | $20,000 |
| Interest Income | $4,557,000 | $3,351,000 | $49,000 | $20,000 |
| Normalized Income | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,530,678 |
| Net Income From Continuing And Discontinued Operation | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Total Operating Income As Reported | $-55,973,000 | $-33,021,000 | $-59,268,000 | $-47,778,900 |
| Net Income Common Stockholders | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-48,707,500 |
| Net Income | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Net Income Including Noncontrolling Interests | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Net Income Continuous Operations | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Pretax Income | $-51,411,000 | $-29,358,000 | $-59,242,000 | $-47,759,000 |
| Interest Income Non Operating | $4,557,000 | $3,351,000 | $49,000 | $20,000 |
| Operating Income | $-55,973,000 | $-33,021,000 | $-59,268,000 | $-47,546,900 |
| Special Income Charges | - | - | $0 | $-232,000 |
| Per Share | ||||
| Diluted EPS | $-1.67 | $-1.52 | $-8.51 | $-7.38 |
| Basic EPS | $-1.67 | $-1.52 | $-8.51 | $-7.38 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-278 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-55,338,000 | $-32,453,000 | $-58,736,000 | $-46,815,900 |
| Reconciled Depreciation | $635,000 | $568,000 | $532,000 | $711,100 |
| EBITDA (Bullshit earnings) | $-55,338,000 | $-32,453,000 | $-58,736,000 | $-47,047,900 |
| EBIT | $-55,973,000 | $-33,021,000 | $-59,268,000 | $-47,759,000 |
| Diluted Average Shares | $30,877,029 | $19,354,500 | $6,959,444 | $6,599,946 |
| Basic Average Shares | $30,877,029 | $19,354,500 | $6,959,444 | $6,599,946 |
| Diluted NI Availto Com Stockholders | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-48,707,500 |
| Tax Provision | $7,000 | $4,000 | $6,000 | $3,400 |
| Research And Development | $39,375,000 | $20,022,000 | $44,377,000 | $35,407,800 |
| Selling General And Administration | $17,084,000 | $14,063,000 | $14,664,000 | $13,248,000 |
| Other Gand A | $17,084,000 | $14,063,000 | $14,664,000 | $3,392,000 |
| Total Unusual Items | - | - | $0 | $-232,000 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $-232,000 |
| Write Off | - | - | $0 | $232,000 |
| Insurance And Claims | - | - | $1,379,000 | $578,000 |
| Rent And Landing Fees | - | - | $419,000 | $377,000 |
| Salaries And Wages | - | - | $6,285,000 | $6,105,000 |
| Preferred Stock Dividends | - | - | - | $945,100 |
Fetched: 2026-06-09
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Total Assets | $84,341,000 | $123,653,000 | $21,089,000 | $74,643,400 |
| Total Non Current Assets | $2,265,000 | $2,981,000 | $3,582,000 | $3,645,400 |
| Other Non Current Assets | $454,000 | $726,000 | - | - |
| Current Assets | $82,076,000 | $120,672,000 | $17,507,000 | $70,998,000 |
| Other Current Assets | $1,594,000 | $1,506,000 | $802,000 | $71,800 |
| Cash Cash Equivalents And Short Term Investments | $80,482,000 | $119,166,000 | $16,638,000 | $68,135,300 |
| Cash And Cash Equivalents | $67,131,000 | $119,166,000 | $16,638,000 | $68,135,300 |
| Non Current Prepaid Assets | - | $101,000 | $101,000 | $100,900 |
| Non Current Deferred Assets | - | $625,000 | $714,000 | $468,200 |
| Current Deferred Assets | - | $74,000 | $67,000 | $116,900 |
| Receivables | - | - | $802,700 | $2,745,800 |
| Other Receivables | - | - | $802,700 | $2,745,800 |
| Prepaid Assets | - | - | - | $2,336,100 |
| Debt | ||||
| Total Debt | $1,509,000 | $2,120,000 | $2,711,000 | $3,038,700 |
| Long Term Debt And Capital Lease Obligation | $948,000 | $1,570,000 | $2,120,000 | $2,605,400 |
| Current Debt And Capital Lease Obligation | $561,000 | $550,000 | $591,000 | $433,300 |
| Current Debt | - | - | $105,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $13,951,000 | $9,367,000 | $9,009,000 | $9,928,100 |
| Total Non Current Liabilities Net Minority Interest | $1,339,000 | $4,244,000 | $4,435,000 | $4,163,000 |
| Non Current Deferred Liabilities | $391,000 | $2,674,000 | $2,315,000 | $1,557,600 |
| Current Liabilities | $12,612,000 | $5,123,000 | $4,574,000 | $5,765,100 |
| Current Deferred Liabilities | $2,588,000 | $791,000 | $714,000 | $1,244,000 |
| Payables And Accrued Expenses | $6,103,000 | $2,163,000 | $2,932,000 | $4,021,600 |
| Payables | $653,000 | $1,547,000 | $2,473,000 | $2,758,600 |
| Accounts Payable | $653,000 | $1,547,000 | $2,473,000 | $2,758,600 |
| Current Notes Payable | - | $0 | $105,000 | $0 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Total Equity Gross Minority Interest | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Stockholders Equity | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Gains Losses Not Affecting Retained Earnings | $5,000 | $0 | - | - |
| Other Equity Adjustments | $5,000 | - | - | - |
| Retained Earnings | $-407,632,000 | $-356,214,000 | $-326,852,000 | $-267,604,000 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Treasury Shares Number | $4,522 | $4,522 | $4,521 | $4,522 |
| Ordinary Shares Number | $28,996,959 | $27,025,209 | $7,310,881 | $6,884,698 |
| Share Issued | $29,001,481 | $27,029,731 | $7,315,402 | $6,889,220 |
| Tangible Book Value | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Invested Capital | $70,390,000 | $114,286,000 | $12,185,000 | $64,715,300 |
| Working Capital | $69,464,000 | $115,549,000 | $12,933,000 | $65,232,900 |
| Capital Lease Obligations | $1,509,000 | $2,120,000 | $2,606,000 | $3,038,700 |
| Total Capitalization | $70,390,000 | $114,286,000 | $12,080,000 | $64,715,300 |
| Treasury Stock | $3,968,000 | $3,968,000 | $3,968,000 | $3,968,100 |
| Additional Paid In Capital | $481,956,000 | $474,441,000 | $342,893,000 | $336,280,500 |
| Capital Stock | $29,000 | $27,000 | $7,000 | $6,900 |
| Common Stock | $29,000 | $27,000 | $7,000 | $6,900 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | $391,000 | $2,674,000 | $2,315,000 | $1,557,600 |
| Long Term Capital Lease Obligation | $948,000 | $1,570,000 | $2,120,000 | $2,605,400 |
| Current Deferred Revenue | $2,588,000 | $791,000 | $714,000 | $1,244,000 |
| Current Capital Lease Obligation | $561,000 | $550,000 | $486,000 | $433,300 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,360,000 | $1,619,000 | $337,000 | $66,200 |
| Current Accrued Expenses | $5,450,000 | $616,000 | $459,000 | $1,263,000 |
| Net PPE | $1,811,000 | $2,255,000 | $2,767,000 | $3,076,300 |
| Accumulated Depreciation | $-1,404,000 | $-1,254,000 | $-1,193,000 | $-1,268,800 |
| Gross PPE | $3,215,000 | $3,509,000 | $3,960,000 | $4,345,100 |
| Leases | $221,000 | $214,000 | $214,000 | $214,400 |
| Other Properties | $2,881,000 | $3,273,000 | $3,706,000 | $4,054,500 |
| Machinery Furniture Equipment | $113,000 | $22,000 | $40,000 | $76,200 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $13,351,000 | $0 | - | - |
| Non Current Accrued Expenses | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-06-09
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-42,288,000 | $-25,874,000 | $-49,928,000 | $-45,456,900 |
| Operating Activities | ||||
| Operating Cash Flow | $-42,097,000 | $-25,813,000 | $-49,716,000 | $-45,256,500 |
| Cash Flow From Continuing Operating Activities | $-42,097,000 | $-25,813,000 | $-49,716,000 | $-45,256,500 |
| Operating Gains Losses | - | $6,000 | $78,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-191,000 | $-61,000 | $-212,000 | $-200,400 |
| Investing Cash Flow | $-13,148,000 | $-61,000 | $-740,000 | $-200,400 |
| Cash Flow From Continuing Investing Activities | $-13,148,000 | $-61,000 | $-740,000 | $-200,400 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $3,009,000 | $129,379,000 | $104,000 | $4,438,900 |
| Financing Cash Flow | $3,210,000 | $128,402,000 | $-1,041,000 | $10,483,900 |
| Cash Flow From Continuing Financing Activities | $3,210,000 | $128,402,000 | $-1,041,000 | $10,483,900 |
| Net Common Stock Issuance | $3,009,000 | $129,379,000 | $-70,000 | $4,438,900 |
| Common Stock Issuance | $3,009,000 | $129,379,000 | $104,000 | $4,438,900 |
| Repurchase Of Capital Stock | - | - | $-174,000 | - |
| Other | ||||
| Repayment Of Debt | $0 | $-985,000 | $-1,034,000 | $-3,000 |
| End Cash Position | $67,131,000 | $119,166,000 | $16,638,000 | $68,135,300 |
| Beginning Cash Position | $119,166,000 | $16,638,000 | $68,135,000 | $103,108,300 |
| Changes In Cash | $-52,035,000 | $102,528,000 | $-51,497,000 | $-34,973,000 |
| Proceeds From Stock Option Exercised | $201,000 | $8,000 | $63,000 | $6,048,000 |
| Net Issuance Payments Of Debt | $0 | $-985,000 | $-1,034,000 | $-3,000 |
| Net Short Term Debt Issuance | $0 | $-985,000 | $-1,034,000 | $0 |
| Short Term Debt Payments | $0 | $-985,000 | $-1,034,000 | $0 |
| Net Investment Purchase And Sale | $-12,957,000 | $0 | - | - |
| Sale Of Investment | $12,027,000 | $0 | - | - |
| Purchase Of Investment | $-24,984,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-191,000 | $-61,000 | $-212,000 | $-200,400 |
| Purchase Of PPE | $-191,000 | $-61,000 | $-212,000 | $-200,400 |
| Change In Working Capital | $4,760,000 | $793,000 | $2,027,000 | $-1,917,900 |
| Change In Other Working Capital | $-222,000 | $516,000 | $206,000 | $-1,004,600 |
| Change In Other Current Liabilities | $-611,000 | $-495,000 | $-433,000 | $-677,000 |
| Change In Payables And Accrued Expense | $5,681,000 | $522,000 | $-934,000 | $1,686,900 |
| Change In Prepaid Assets | $-88,000 | $250,000 | $3,188,000 | $-1,923,200 |
| Stock Based Compensation | $4,315,000 | $2,182,000 | $3,336,000 | $3,480,700 |
| Amortization Of Securities | $-389,000 | $0 | - | - |
| Depreciation Amortization Depletion | $635,000 | $568,000 | $532,000 | $711,100 |
| Depreciation And Amortization | $635,000 | $568,000 | $532,000 | $711,100 |
| Depreciation | $635,000 | $568,000 | $532,000 | $711,100 |
| Gain Loss On Sale Of PPE | $0 | $6,000 | $0 | - |
| Net Income From Continuing Operations | $-51,418,000 | $-29,362,000 | $-59,248,000 | $-47,762,400 |
| Net Business Purchase And Sale | - | $0 | $-528,000 | $0 |
| Purchase Of Business | - | $0 | $-528,000 | $0 |
| Common Stock Payments | - | - | $-174,000 | - |
| Net Long Term Debt Issuance | - | - | $-1,500 | $-3,000 |
| Long Term Debt Payments | - | - | $-1,500 | $-3,000 |
| Other Non Cash Items | - | - | $3,559,000 | - |
| Asset Impairment Charge | - | - | $0 | $232,000 |
| Gain Loss On Investment Securities | - | - | $78,000 | - |
| Issuance Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $300 |
| Income Tax Paid Supplemental Data | - | - | - | $3,400 |
| Long Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | - |
| Change In Other Current Assets | - | - | - | - |
| Change In Receivables | - | - | - | - |
| Changes In Account Receivables | - | - | - | - |
Fetched: 2026-06-09